Imjudo & Imfinzi PMS

Launched by ASTRAZENECA · Aug 6, 2024

Keywords

ClinConnect Summary

This clinical trial, called Imjudo & Imfinzi PMS, is looking at the safety and effectiveness of two medications, Imjudo and Imfinzi, for treating a type of liver cancer known as hepatocellular carcinoma. The goal of the study is to see how these drugs work in real-life situations for patients in Korea who meet certain criteria for their use. The trial is not yet recruiting participants, which means they are still in the planning phase.

To be eligible for the trial, patients must be able to use these drugs as approved in Korea and provide written consent to participate. However, those currently involved in other clinical trials or using the drugs for reasons not approved in South Korea will not be able to join. If selected, participants can expect careful monitoring while receiving the medications, helping researchers understand how well they work and how safe they are in everyday use.

Gender

ALL

Eligibility criteria

• Inclusion criteria:
• • 1. Patients eligible for the study drugs according to the approved label in Korea
• • 2. Provision of signed and dated written informed consent by the patient or legally acceptable representative
• Exclusion criteria:
• • 1. Other off-label indications according to the approved label in South Korea
• • 2. Current participation in any interventional trial